Short Summary
Torrent Pharma Limited filed an appeal challenging the order dated February 1, 2021, passed by the Assistant Controller. The said order rejected the patent application for 'Use of a Thiazolo Pyrimidinone' on grounds of lack of inventive step and non-patentability under Sections 3(e) and 3(d) of the Patents Act.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Torrent Pharma Limited vs Controller General Of Patents is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Tvs Motor Company LimitedvsThe Controller of Patents & Designs
TVS Motor Company appealed a rejection order issued by The Controller of Patents & Designs regarding its patent application for a Vehicle Monitoring System. The appellant argued that certain prior art documents did not qualify as prior art or failed to disclose the claimed invention's features, particularly data transmission capabilities when the vehicle is switched off. The High Court set aside the impugned order and remanded the matter for fresh consideration.
M/S Coral Drugs Private LimitedvsThe Assistant Controller Of Patents And Designs and Anr
The appeal challenged the Assistant Controller's refusal of a patent application (No. 201717022856) due to lack of inventive step. The appellant sought permission to amend its claims, which were subsequently accepted by the High Court provided they did not broaden the scope of the original claims.
Novo Nordisk A/SvsDr Reddys Laboratories Limited & Anr.
Novo Nordisk appealed a rejection of its interlocutory injunction application regarding the import and sale of Semaglutide, claiming infringement of its patent. The court dismissed the appeal, noting that the suit patent was set to expire shortly, but also found prima facie evidence suggesting the suit patent could be challenged for obviousness based on prior art (Genus Patent IN'964).
F.Hoffmann-La Roche AgvsThe Controller of Patents and Designs, Government of India
F.Hoffmann-La Roche Ag filed an appeal challenging an order passed by The Controller of Patents and Designs regarding Patent No. 208718. However, the petitioner subsequently informed the court that the patent had expired on October 1, 2019.
Chugai Seiyaku Kabushiki KaishavsLupin Limited
Chugai Seiyaku Kabushiki Kaisha filed suit against Lupin Limited regarding the public display of a specific product by the defendant. The court accepted that if the defendants modify their website to include an asterisk stating 'for the purposes of research under Section 107A of the Patents Act, 1970', it would suffice to address the plaintiff's grievance.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.